Associations Between Components of Metabolic Syndrome and Cognition in Patients With Schizophrenia
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The metabolic syndrome and cognitive dysfunctions are common in patients with schizophrenia, yet there is no general consensus concerning the effects of the components of the metabolic syndrome on various cognitive domains. The goal of this study was to investigate the relationship between components of the metabolic syndrome and cognition in patients with schizophrenia. Components of the metabolic syndrome and neurocognitive functioning were assessed in 68 patients with schizophrenia. The Brief Assessment of Cognition in Schizophrenia (BACS) was used to assess neurocognition. Hyperglycemia and hypertension were the only components of the metabolic syndrome found to be associated with cognitive functioning. Patients with schizophrenia who were hypertensive showed cognitive impairments in 2 domains, with a negative association found between hypertension and verbal memory (P=0.047) and verbal fluency (P=0.007). Hyperglycemia was associated with higher scores on verbal memory (P=0.01) and verbal fluency (P<0.001). It appears that medical treatment of certain components of the metabolic syndrome could affect cognitive performance in patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
(2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1069 · Cited by 988
Hypertension Is Related to Cognitive Impairment: A 20-Year Follow-up of 999 Men
Kilander, L., Nyman, H., Boberg, M., Hansson, L., & Lithell, H. (1998) · Hypertension · doi:10.1161/01.hyp.31.3.780 · Cited by 630
Mediterranean Diet, Cognitive Function, and Dementia: A Systematic Review
Lourida, I., Soni, M., Thompson-Coon, J., Purandare, N., Lang, I. A., Ukoumunne, O. C., & Llewellyn, D. J. (2013) · Epidemiology · doi:10.1097/ede.0b013e3182944410 · Cited by 521
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
KEEFE, R., HARVEY, P., GOLDBERG, T., GOLD, J., WALKER, T., KENNEL, C., & HAWKINS, K. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.03.024 · Cited by 342
The metabolic effects of antipsychotic medications
Newcomer, J. W., & Haupt, D. W. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100803 · Cited by 315
The Metabolic Syndrome and Development of Cognitive Impairment Among Older Women
Yaffe, K., Weston, A. L., Blackwell, T., & Krueger, K. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.566 · Cited by 220
Associations Between Bipolar Disorder and Metabolic Syndrome: A Review
Taylor, V., & MacQueen, G. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0704 · Cited by 152 · cited 2×
“complete the cognitive tests; (5) stable dose of primary typical or atypical antipsychotic for at least 4 weeks; (6) no physical health problem requiring frequent changes in medications; and (7) capacity and willingness to give written informed consent.”
Background
Cited by
Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
Salehi, B., Berkay Yılmaz, Y., Antika, G., Boyunegmez Tumer, T., Fawzi Mahomoodally, M., Lobine, D., Akram, M., Riaz, M., Capanoglu, E., Sharopov, F., et al. (2019) · Biomolecules · doi:10.3390/biom9080356 · Cited by 416
Dauwan, M., Begemann, M. J. H., Heringa, S. M., & Sommer, I. E. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv164 · Cited by 393
Bora, E., Akdede, B. B., & Alptekin, K. (2017) · Psychological Medicine · doi:10.1017/s0033291716003366 · Cited by 219
“We contacted authors of these papers but we were not able to obtain this data from the authors (Wysokiński et al. 2013; Goughari et al. 2015).”
MethodAntipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
MacKenzie, N. E., Kowalchuk, C., Agarwal, S. M., Costa-Dookhan, K. A., Caravaggio, F., Gerretsen, P., Chintoh, A., Remington, G. J., Taylor, V. H., Müeller, D. J., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00622 · Cited by 205
“The dose of AP medication may have an effect on cognition, with higher AP doses, as well as, AP polypharmacy, reported to be associated with worse cognitive functioning (49, 50).”
BackgroundInfluentialSchizophrenia, Curcumin and Minimizing Side Effects of Antipsychotic Drugs: Possible Mechanisms
Rabiee, R., Hosseini Hooshiar, S., Ghaderi, A., & Jafarnejad, S. (2023) · Neurochemical Research · doi:10.1007/s11064-022-03798-4 · Cited by 11
Metadata
- Authors
- S. GOUGHARI, A., MAZHARI, S., POURRAHIMI, A. M., SADEGHI, M. M., & NAKHAEE, N.
- Venue
- Journal of Psychiatric Practice
- Published
- 2015-05
- Volume
- 21
- Issue
- 3
- Pages
- 190-197
- ISSN
- 1527-4160 (ISSN-L)
- 1538-1145
- OpenAlex
- W567737511
- Cited by
- 35
- References
- 8
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Associations Between Components of Metabolic Syndrome and Cognition in Patients With Schizophrenia. https://app.cochat.ai/papers/10.1097/pra.0000000000000065
- The paper
- S. GOUGHARI, A., MAZHARI, S., POURRAHIMI, A. M., SADEGHI, M. M., & NAKHAEE, N. (2015). Associations Between Components of Metabolic Syndrome and Cognition in Patients With Schizophrenia. Journal of Psychiatric Practice. https://doi.org/10.1097/pra.0000000000000065
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.